Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

pegylated liposomal doxorubicin / Generic mfg.

NCT00004112: Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Completed

rituximab, Rituxan, CHOP regimen, cyclophosphamide, vincristine, doxorubicin, prednisolone, cyclophosphamide, chemotherapy, doxorubicin hydrochloride, Lipodox, Lipodox 50, and Doxil, prednisone, Prednisone Intensol, Deltasone, Rayos, steroid, vincristine sulfate, Oncovin

University of Nebraska, National Cancer Institute (NCI)

Lymphoma

12/00

03/03

NCT00344422: Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Completed

198

Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Multiple Myeloma, Myeloma, M-Protein, Myeloma Proteins

06/04

NCT00097981: A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Completed

225

Thalidomide, Dexamethasone, DOXIL

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Multiple Myeloma

10/07

10/09

NCT00103506 / 2004-001842-34: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Completed

646

US, Canada, Europe, RoW

Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)

Janssen Research & Development, LLC

Multiple Myeloma

05/14

06/14



	Diseases Companies Products Productz Mechanisms of Action Sites